Saturday, October 21, 2017

The Liver Meeting 2017 - Tenofovir exalidex safe, well-tolerated in early HBV trial

Tenofovir exalidex safe, well-tolerated in early HBV trial
October 21, 2017
Tenofovir exalidex, a novel prodrug of tenofovir, appeared safe and well-tolerated in patients with hepatitis B, according to a presentation at The Liver Meeting 2017.

“The final results from this study have confirmed a clear way forward for developing TXL so that it can become a key component of future, successful combination treatments for HBV infection,” Tawesak Tanwandee, MD, associate professor of medicine and head of the division of gastroenterology in the department of medicine at Siriraj Hospital, Mahidol University in Bangkok, Thailand, told Healio.com/Hepatology. “This is important for patients, and those who treat them, because we need to have many treatment choices for this widespread, and complicated, disease.”


Coverage At Healio

No comments:

Post a Comment